• Shenzhen Salubris Pharmaceuticals Co., Ltd. was established on November 3rd, 1998 in Shenzhen, China.

  • Production of the first product Xindakang (Azithromycin Dispersible Tablets) started.

  • Production of the first powder injection product Xinlixin (Cefuroxime Sodium for Injection) started.

  • Taijia (Clopidogrel Bisulfate Tablets) started sole production in China, and was listed as Shenzhen High-tech Project.

  • The API facility was established and put into production

  • Salubris was rewarded as a “National High-tech Enterprise”.

  • The Salubris (Shandong) Production Base for intermediates and APIs was established.

  • Shenzhen Salubris Pharmaceuticals Co., Ltd. was successfully listed on the Shenzhen Stock Exchange.

  • Salubris was certified as “Key High-tech Enterprise of National Torch Program”.

  • Tsinghua University - Salubris Joint Research Center for Small Molecule Drugs was set up.

  • The Salubris (Pingshan) Industrial Base for medical devices and finished medicinal products was established.

  • Salubris Technology Center was assessed as “National Level Industrial Technology Center”.

  • The Salubris (Dayawan) Production Base for oral dosage formulation and chemical APIs was established.

  • Shenzhen Post-doctoral Innovative Practice Base (municipal level) was founded.

  • Allisartan Isoproxil Tablets (Xinlitan) was awarded as “Top 10 Blockbuster Prescription Drugs in 2013 in China”

  • The production base of Genemen Biotech (Suzhou) Co., Ltd. joined in Salubris.

  • The R&D base of Genekey Biotech (Chengdu) Co., Ltd. joined in Salubris

  • The propaganda film of Salubris was on display on Times Square, New York

  • Salubris acquired Shenzhen Keyidun Biomedical Technology Co., Ltd.

  • Taijia® received Chinese Patent Gold Award.

  • Salubris started strategic alliance with the National Key Biotherapy Laboratory of Sichuan University for innovative drugs.

  • Salubris acquired Alain Medical (Beijing) Co., Ltd.

  • Salubris received the award of “National Demonstration Enterprise in Technology Innovation”.

  • Salubris solely financed the “Whole-hearted Care” Program, covering the whole-process management on medication donation for patients with acute coronary syndrome (ACS).

  • Taijia was approved and on the first list of products with quality consistency evaluation(QCE).

  • Genemen Biotech (Suzhou) Co., Ltd was equipped with production plat of Flex Factory.

  • Salubris Biotherapeutics, Inc. was founded in the United States.

  • Xinlitan (Allisartan Isoproxil Tablets) was included in the National Reimbursement Drugs List.

  • Salubris invested in GO Therapeutics, Inc.